Table 4

Association of alpha 1-antitrypsin protease inhibitor (PI) status and height (cm) adjusted for age and sex

Regression coefficient (95% CI)
CohortMS vs MMMZ vs MM†
BO2.31 (−0.24 to 4.86)7.33** (2.36 to 12.30)
CaPS0.27 (−0.97 to 1.51)0.55 (−1.08 to 2.18)
ELSA0.20 (−0.40 to 0.81)2.02**** (1.12 to 2.92)
HAS0.24 (−3.04 to 3.51)−0.26 (−3.69 to 3.18)
HCS−0.10 (−0.87 to 0.67)1.23* (0.09 to 2.37)
LBC19210.44 (−1.55 to 2.43)1.06 (−1.89 to 4.00)
NSHD0.68 (−0.11 to 1.47)1.84** (0.64 to 3.04)
WHII0.23 (−0.34 to 0.81)1.24** (0.34 to 2.14)
Combined FE0.28 (−0.03 to 0.59)1.50**** (1.03 to 1.97)
Combined RE0.28 (−0.03 to 0.59)1.51**** (1.04 to 1.97)
Estimated var‡2.77e−13 (1.06e−26 to 7.27e+00)1.67e−12 (1.59e−25 to 1.76e+01)
  • Estimates for PI-SS, SZ and ZZ are provided in the online supplement.

  • *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

  • †Exact p values for PI-MZ—height were 3.6×10−10 (FE) and 2.9×10−10 (RE).

  • ‡Estimated variance of the random slope on carrier status modelled by the RE model.

  • BO, Boyd Orr; CaPS, Caerphilly Prospective Study; ELSA, English Longitudinal Study of Ageing; FE, fixed effect; HAS; Hertfordshire Ageing Study; HCS, Hertfordshire Cohort Study; LBC1921, Lothian Birth Cohort 1921; NSHD, MRC National Survey of Health and Development; RE, random effect; WHII, Whitehall II Study.